![[current-page:title] logo](/sites/default/files/styles/logo/public/default_images/_no-logo.png?itok=8OH0tuUw){kind=logo}
Founded
Address
Avlar Bioventures Ltd
Church Lane
Highfield Court Madingley
Cambridge
CB3 8AG
United Kingdom
Phone
Email
Website
KANDO id: 23999
Company type
Venture investor in biotechnology and healthcareFunds managed
| Fund | Type | Vintage | Currency | Committed capital |
|---|---|---|---|---|
| Avlar Bioventures Fund II LP | Venture | 2001 | GBP | 43,000,000 |
| First Cambridge Gateway LP | Venture | 2000 | GBP | 35,300,000 |
| Avlar Bioventures Fund I LP | Venture | 1999 | GBP | 20,700,000 |
Funding rounds
Investment activity status
Active investor
Selected investments
Displaying 1 - 14 of 14| Company | Profile | Country | Funding | ||
|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Amura Ltd | A structure-based drug discovery business specialising in diseases such as osteoporosis, osteoarthritis, bone metasta. Secondary sale in February 2005 | N/A | ||
|
|
Cambridge Biotechnology Ltd | Small molecule drugs for pain and obesity. Aquired by Biovitrum AB in April 2005. | N/A | ||
|
|
CellCentric Ltd | One of the leaders in the commercial exploitation of epigenetics and mechanisms that determine cell fate. | N/A | ||
|
|
CeNeS Pharmaceuticals PLC | N/A | |||
|
|
Cozart PLC | N/A | |||
|
|
De Novo Pharmaceuticals Ltd | A world leader in in-silico structure-based drug design, de novo drug design. | N/A | ||
|
|
Immbio | N/A | |||
|
|
Medical Device Innovations Ltd | N/A | |||
|
|
PAION | N/A | |||
|
|
Paradigm Therapeutics Ltd | Drug discovery platform company Acquired by Takeda Pharmaceutical Company Ltd in December 2004. | N/A | ||
|
|
Prosarix Ltd | N/A | |||
|
|
Purely Proteins | N/A | |||
|
|
Sangamo BioScience | N/A | |||
|
|
Sterix Ltd | N/A |